Core Viewpoint - Lepu Biopharma-B (02157.HK) has entered into a CDMO service framework agreement with Lepu Medical, which will allow the company to provide CDMO technical services to Lepu Medical and its affiliates starting from November 28, 2025 [1] Group 1: Company Overview - The company is primarily engaged in the research and development of its candidate drugs and operates a GMP-compliant bioreactor production line that has been in operation since the end of 2019 [1] - The company has a comprehensive production management structure and a professional production team with rich experience, complementing its production facilities [1] Group 2: Production Capacity and Financial Implications - The company has established upstream and downstream antibody raw material production lines, formulation production lines, and other production facilities that meet GMP standards, ensuring high-quality drug production [1] - The board believes that entering into the CDMO service framework agreement will enable the company to utilize its surplus production capacity more effectively, thereby generating additional cash flow for the overall business [1]